



**TTK Healthcare
LIMITED**

TTKH:SEC:GJ:085:22

May 23, 2022

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Scrip Code: 507747

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra East
Mumbai 400 051

Scrip Code: TTKHLTCARE

Dear Sirs,

**Re : Outcome of the Board Meeting – Disclosure under Regulation 30 of SEBI
(LODR) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, *inter alia* considered and approved / recommended the following:

- (i) Dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each, for the financial year ended 31st March, 2022 which shall be paid / despatched within 21 days from the date of AGM, subject to the approval of the Shareholders;
- (ii) The 64th Annual General Meeting of the Company has been scheduled to be held on **Wednesday**, the **3rd August, 2022**, through Video Conferencing / Other Audio Visual Means (VC / OAVM);
- (iii) We enclose a brief highlights of the Audited Financial Statements (**in Annexure-1**).

We request you to kindly take the above information / documents on record.

The meeting of the Board of Directors was held through video conferencing which commenced at 12 noon and concluded at 12.50 p.m.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a



TTK Healthcare LIMITED

ANNEXURE-1

HIGHLIGHTS OF THE AUDITED FINANCIAL RESULTS **FOR THE YEAR ENDED 31st MARCH, 2022**

	(Rs. in lakhs)	
Particulars	2021-22	2020-21
Revenue from Operations	59,923.99	47,605.86
Other Income	1,633.06	993.47
Total Income	61,557.05	48,599.33
Cost of Materials Consumed	28,149.47	20,932.49
Employee Benefits Expense	10,284.24	9,369.79
Other Expenses	19,306.55	15,371.63
Profit before Finance Costs, Depreciation & Exceptional Items	3,816.79	2,965.42
Finance Costs	323.75	171.09
Depreciation	1,258.36	1,301.96
Exceptional Item – Profit on sale of land / Interest on Tax Refund	249.05	809.79
Profit before Tax from continuing operations	2,483.73	2,262.16
Less: Tax Expense		
Current Tax	743.67	747.91
Tax relating to earlier years	-	(1,964.81)
Deferred Tax	(110.96)	(199.11)
Profit after Tax from continuing operations	1,851.02	3,678.17
Profit from Human Pharma Division held for sale in subsequent year	3,294.14	1,443.03
Less: Tax expense for Human Pharma Division held for sale in subsequent year	986.33	477.09
Profit after Tax from Human Pharma Division held for sale in subsequent year	2,307.81	965.94
Profit after Tax (including Human Pharma Division)	4,158.83	4,644.11

- Note:** (i) In terms of the decision taken by the Audit Committee and the Board of Directors of the Company in their meeting held on 21st March, 2022 and subsequent consent from the Members of the Company by means of a Special Resolution passed through Postal Ballot Process on 23rd April, 2022, the Human Pharma Division (Undertaking) of the Company stands transferred, as a going concern, on a slump sale basis, for a consideration of Rs.805 crores (subject to adjustment for working capital and other items that are customary in such transactions) to M/s BSV Pharma Private Limited (BSV), with effect from 9th May, 2022.
- (ii) Total Income of Human Pharma Division during the current year was Rs.19,812.58 lakhs (Previous Year - Rs.16,053.47 lakhs) and its Total Expenses was Rs.16,518.44 lakhs (Previous Year - Rs.14,610.44 lakhs).



Regd. Office : No. 6, Cathedral Road, Chennai - 600 086, INDIA
Phone : 91-44-28116106 - 08, Fax : 91-44-28116387
Email : info@ttkhealthcare.com Website : www.ttkhealthcare.com
CIN : L24231TN1958PLC003647